Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company" and "Zhongsheng Pharmaceutical") was founded in 1979. It is an A-share listed company integrating drug research and development, production and sales.

The company implements the value of "patient interests first", adheres to the corporate purpose of "caring for life with high-quality products and serving healthy people with high-quality", and is based on the treatment fields of ophthalmology, cardiovascular, respiratory, digestive and other treatments, with pharmaceutical manufacturing as its core business. , adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with innovative drugs as the leader in development, traditional Chinese patent medicine as the cornerstone of business, and chemical generic drugs as the beneficial support, and be determined to become China's advanced pharmaceutical and health industry group.

The company's main business covers the research and development, production and sales of traditional Chinese medicines, chemical medicines, Chinese medicinal materials, Chinese herbal medicines, chemical raw materials, and investment in ophthalmology related industries. It has ten subsidiaries covering pharmaceutical, pharmaceutical, trade, innovative R&D and ophthalmology investment. There are four major production bases in Dongguan, Guangzhou, Zhaoqing and Qujing.

The company adheres to the development concept of "R&D and innovation are the primary productive forces", aims to "meet unmet clinical needs" and "research and development varieties with unique clinical value". By establishing a multi-modal virtuous cycle R&D ecosystem, we are committed to Research and development of innovative drugs for public health and safety, major chronic diseases. Through its stake in the South China New Drug Creation Center, the company introduced the Guangdong Provincial Innovation Team, and strategic cooperation with WuXi AppTec and the National Clinical Medical Research Center for Respiratory Diseases (Academician Zhong Nanshan’s team), focusing on influenza and non-alcoholic steatohepatitis ( NASH), ophthalmology, tumors and metabolic diseases and other special areas have been carried out to develop innovative drugs. At the same time, the company seized the historic opportunities of generic drug consistency evaluation and national centralized procurement, and steadily promoted the consistency evaluation of generic drug.

The company continues to implement the business strategy of "full products, all terminals, and all channels", builds a chronic disease product line around core products, deepens the grassroots pharmaceutical market in small and medium-sized cities, increases county-level terminal coverage, innovates professional academic promotion system, and through digitalization Technology empowers marketing and explores new business models.